Precision BioSciences Stock
Precision BioSciences is a biotechnology company dedicated to improving life.
About Precision BioSciences Stock
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.
Funding History
| March 2006 | $0 |
|---|---|
| May 2015 | $25.6M |
| June 2018 | $110M |
| March 2019 | $39.5M |
Management
Co-Founder and Chief Executive Officer
Matthew Kane
Director of Human Resources
Molly Lukes
Chief Development Officer, Executive Vice President
David Thomson
CEO, Elo
Fayaz Khazi
Co-Founder and Chief Technical Officer
Jeff Smith
Co-Founder and Chief Scientific Officer
Derek Jantz
Press
How To Spot A Synthetic Biology Unicorn
Forbes - Sep, 27 2019
Uber and Other IPOs Set for an Index Bounce
Wall Streets Journal - Jun, 14 2019
Reshaping human health and changing lives through gene editing
TechCrunch - May, 21 2016
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Precision BioSciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
